ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1040

Impact of Clinical Pharmacist-Directed Patient Education on Medication Adherence and Clinical Outcomes in Patients with Inflammatory Arthritis

Cristina Hurley1, Megha Kotha2, Jisna Paul3 and Jeff Barbee4, 1Carilion Clinic, Roanoke, VA, 2Ohio State University, Columbus, OH, 3Division of Rheumatology and Immunology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, Columbus, OH, 4Ohio State University Wexner Medical Center, Columbus

Meeting: ACR Convergence 2025

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), education, patient, Health Services Research, Patient reported outcomes, quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1038–1054) Health Services Research Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: This study assesses the impact of a clinical pharmacist-directed intervention on medication adherence and clinical outcomes in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving non-infusion disease-modifying antirheumatic drugs (DMARDs). Previous studies on patient education interventions in rheumatology have yielded mixed results due to variability in study populations and educational methods. Pharmacist-led interventions in other chronic diseases, such as hypertension and diabetes, have demonstrated improved disease management and adherence, but data on their effectiveness in inflammatory arthritis remains limited.

Methods: A prospective, controlled study was conducted from July to December 2024 at Ohio State University (OSU) Rheumatology. Fifty adult patients were enrolled and assigned to either a pharmacist-directed intervention group or a usual care control group. The intervention group received pharmacist-led education, drug toxicity monitoring, and follow-up. Surveys administered at baseline and follow-up included the Morisky Medication Adherence Scale (MMAS), the Routine Assessment of Patient Index Data 3 (RAPID3), and three medication knowledge questions. Statistical analyses included Pearson’s chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables. The primary outcome was MMAS score, with RAPID3 and medication knowledge responses as secondary outcomes.

Results: Baseline characteristics were similar between groups, except for a higher prevalence of tobacco use in the intervention group (p = 0.03). No significant differences were found in MMAS scores (p = 0.84), RAPID3 dichotomous outcomes (p = 0.04), or medication knowledge responses. Participants with higher education levels were more likely to report confidence in their medication knowledge. While the intervention group showed a trend toward improved disease control based on RAPID3 scores, this difference did not reach statistical significance. Correlation analysis revealed associations between gender and DMARD failure (r = 0.37, p < 0.01), race and anti-CCP positivity (r = 0.31, p < 0.05), and tobacco use with education level (r = -0.41, p < 0.01). The strongest correlation was between RF and CCP positivity (r = 0.83, p < 0.001).

Conclusion: Pharmacist-led patient education did not significantly improve medication adherence or clinical outcomes in this small cohort. However, trends in RAPID3 scores suggest a potential benefit in disease control. Confidence in medication knowledge was higher in those with greater educational attainment. Further large-scale studies are warranted to determine the impact of pharmacist-led education in inflammatory arthritis, similar to its demonstrated benefits in other chronic conditions such as hypertension and diabetes.

Supporting image 1

Supporting image 2


Disclosures: C. Hurley: None; M. Kotha: None; J. Paul: None; J. Barbee: None.

To cite this abstract in AMA style:

Hurley C, Kotha M, Paul J, Barbee J. Impact of Clinical Pharmacist-Directed Patient Education on Medication Adherence and Clinical Outcomes in Patients with Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/impact-of-clinical-pharmacist-directed-patient-education-on-medication-adherence-and-clinical-outcomes-in-patients-with-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-clinical-pharmacist-directed-patient-education-on-medication-adherence-and-clinical-outcomes-in-patients-with-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology